

Operating Results for Fiscal 2005 of Individual Member Companies (Non-consolidate)

(Comparative Table of Sales and Income)

Table 2-1 The total of the top 14 members recorded more than 100 billion yen in sales

Unit: million yen

Name of Company	Closing date	Sales			Operating income				Ordinary income				Net Income				Prospects for FY2006					
		FY2004	Change		FY2004	Change		Ratio to sales	FY2004	Change		Ratio to sales	FY2004	Change		Ratio to sales	Sales		Ordinary Income		Net Income	
		FY2005	Amount	%	FY2005	Amount	(%)	(%)	FY2005	Amount	(%)	(%)	FY2005	Amount	(%)	(%)	FY2006	Change from FY2005	FY2006	Change from FY2005	FY 2006	Change from FY2005
		784,848			344,435			43.9	356,696			45.4	235,488			30.0	1.8%		-4.0%		-5.8%	
Takeda Pharmaceutical Company Limited	End of Mar.	840,230	55,382	7.1	345,969	1,534	0.4	41.2	364,439	7,743	2.2	43.4	249,361	13,873	5.9	29.7	855,000	14,770	350,000	-14,439	235,000	-14,361
		625,721			148,274			23.7	169,550			27.1	74,866			12.0	3.3%		-37.8%		-25.1%	
Astellas Pharma Inc.	End of Mar.	576,023	-49,698	-7.9	125,024	-23,250	-15.7	21.7	159,216	-10,334	-6.1	27.6	101,496	26,630	35.6	17.6	595,000	18,977	99,000	-60,216	76,000	-25,496
		307,936			67,634			22.0	69,115			22.4	43,498			14.1	4.2%		-3.5%		-6.6%	
Eisai Co., Ltd.	End of Mar.	331,959	24,023	7.8	65,376	-2,258	-3.3	19.7	67,338	-1,777	-2.6	20.3	43,890	392	0.9	13.2	346,000	14,041	65,000	-2,338	41,000	-2,890
		340,091			64,441			18.9	64,124			18.9	37,548			11.0						
Sankyo Co., Ltd.	End of Mar.	318,127	-21,964	-6.5	46,344	-18,097	-28.1	14.6	48,955	-15,169	-23.7	15.4	23,145	-14,403	-38.4	7.3						
		259,912			54,440			20.9	56,322			21.7	19,303			7.4						
Daiichi Pharmaceutical Co., Ltd.	End of Mar.	278,193	18,281	7.0	71,174	16,734	30.7	25.6	74,160	17,838	31.7	26.7	31,199	11,896	61.6	11.2						
		285,149			46,707			16.4	47,591			16.7	32,778			11.5	-4.1%		-35.4%		-41.2%	
Chugai Pharmaceutical Co., Ltd.	End of Dec.	314,524	29,375	10.3	72,024	25,317	54.2	22.9	76,057	28,466	59.8	24.2	51,367	18,589	56.7	16.3	301,500	-13,024	49,100	-26,957	30,200	-21,167
		232,858			52,685			22.6	56,599			24.3	35,779			15.4	-2.3%		-10.2%		-23.7%	
Taisho Pharmaceutical Co., Ltd.	End of Mar.	223,034	-9,824	-4.2	44,764	-7,921	-15.0	20.1	49,018	-7,581	-13.4	22.0	36,057	278	0.8	16.2	218,000	-5,034	44,000	-5,018	27,500	-8,557
		176,538			39,857			22.6	41,377			23.4	25,007			14.2	3.8%		-8.5%		-17.3%	
Terumo Corporation	End of Mar.	187,238	10,700	6.1	42,516	2,659	6.7	22.7	45,908	4,531	11.0	24.5	31,432	6,425	25.7	16.8	194,400	7,162	42,000	-3,908	26,000	-5,432
		160,378			9,617			6.0	10,620			6.6	6,696			4.2	6.2%		46.9%		+35.8%	
Dainippon Sumitomo Pharma Co., Ltd.	End of Mar.	232,559	72,181	45.0	28,605	18,988	197.4	12.3	27,032	16,412	154.5	11.6	15,389	8,693	129.8	6.6	247,000	14,441	39,700	12,668	20,900	+5,511
		197,914			26,646			13.5	27,758			14.0	14,329			7.2	-4.5%		1.8%		+7.9%	
Wako Pure Chemical Industries, Ltd.	End of Mar.	196,818	-1,096	-0.6	28,620	1,974	7.4	14.5	31,448	3,690	13.3	16.0	19,921	5,592	39.0	10.1	188,000	-8,818	32,000	552	21,500	+1,579
		180,743			24,576			13.6	25,499			14.1	17,787			9.8	8.0%		3.2%		-36.2%	
Shionogi & Co., Ltd.	End of Mar.	183,388	2,645	1.5	25,770	1,194	4.9	14.1	28,107	2,608	10.2	15.3	26,663	8,876	49.9	14.5	198,000	14,612	29,000	893	17,000	-9,663
		164,255			26,365			16.1	26,890			16.4	16,216			9.9	0.2%		2.6%		+12.6%	
Tanabe Seiyaku Co., Ltd.	End of Mar.	163,604	-651	-0.4	25,917	-448	-1.7	15.8	26,315	-575	-2.1	16.1	14,922	-1,294	-8.0	9.1	164,000	396	27,000	685	16,800	+1,878
		144,066			59,368			41.2	61,150			42.4	38,968			27.0	-3.0%		-5.1%		-2.9%	
Ono Pharmaceutical Co., Ltd.	End of Mar.	147,126	3,060	2.1	56,180	-3,188	-5.4	38.2	58,364	-2,786	-4.6	39.7	35,829	-3,139	-8.1	24.4	142,700	-4,426	55,400	-2,964	34,800	-1,029
		78,444			20,500			26.1	20,816			26.5	12,255			15.6	5.0%		-7.5%		+5.4%	
Hisamitsu Pharmaceutical Co., Inc.	End of Feb.	97,169	18,725	23.9	22,865	2,365	11.5	23.5	23,444	2,628	12.6	24.1	13,850	1,595	13.0	14.3	102,000	4,831	25,200	1,756	14,600	+750
Top 14 Total		3,938,853			985,545			25.0	1,034,107			26.3	610,518			15.5	-0.4%		-11.8%		-13.7%	
		4,089,992	151,139	3.8	1,001,148	15,603	1.6	24.5	1,079,801	45,694	4.4	26.4	694,521	84,003	13.8	17.0	3,551,600	-14,489	857,400	-114,258	561,300	-88,770
Total of 16 companies		747,123			84,951			11.4	85,569			11.5	53,652			7.2	3.2%		-8.0%		-1.2%	
		760,703	13,580	1.8	85,971	1,020	1.2	11.3	88,610	3,041	3.6	11.6	53,377	-275	-0.5	7.0	790,450	24,678	82,195	-7,157	52,820	-669
Grand Total of 30 Companies		4,685,976			1,070,496			22.8	1,119,676			23.9	664,170			14.2	0.2%		-11.4%		-12.7%	
		4,850,695	164,719	3.5	1,087,119	16,623	1.6	22.4	1,168,411	48,735	4.4	24.1	747,898	83,728	12.6	15.4	4,342,050	10,189	939,595	-121,415	614,120	-89,439

Notes:

1.The order of listing up is in the order of those with the largest to the smallest amount of sales in FY2005

2.Figures and ratios in the above table are given in units of one million yen. Accordingly, they may differ from those publicized by each company

3.Data for Astellas Pharma Inc, are compared with the total sum of Yamanouchi and Fujisawa in FY2005.

4.Figures and ratios in "Prospect for FY2006" are given based on Table 1-2.

Table 2-2 Operating results for fiscal 2005 of the 16 other members recorded less than 100 billion yen in sales (Non-consolidated)

																						(Unit: million yen)			
		Sales			Operating income				Ordinary income				Net income			Prospects for FY2006									
Name of Company	Closing date	FY2004		Change	FY2004		Ratio to sales	FY2004		Ratio to Sales	FY2004		Ratio to Sales	Sales		Ordinary income		Net income							
		FY2005	Amount		(%)	FY2005		Amount	(%)		(%)	FY2005		Amount	(%)	(%)	FY2005	Amount	(%)	(%)	FY2006	Change from FY2005	FY2006	Change from FY2005	FY2006
		86,340			19,692			22.8	20,266			23.5	12,602			14.6		1.1%		-6.4%		-0.9%			
Santen Pharmaceutical Co., Ltd.	End of Mar.	90,840	4,500	5.2	20,644	952	4.8	22.7	21,376	1,110	5.5	23.5	13,118	516	4.1	14.4	91,800	960	20,000	-1,376	13,000	-118			
		81,587			12,121			14.9	10,539			12.9	9,881			12.1		2.2%		0.1%		13.6%			
Tsumura & Co.	End of Mar.	86,125	4,538	5.6	15,483	3,362	27.7	18.0	14,582	4,043	38.4	16.9	11,621	1,740	17.6	13.5	88,000	1,875	14,600	18	13,200	1579			
		72,979			7,342			10.1	6,742			9.2	3,340			4.6		0.7%		0.7%		8.7%			
Kaken Pharmaceutical Co., Ltd.	End of Mar.	74,001	1,022	1.4	7,785	443	6.0	10.5	7,147	405	6.0	9.7	3,680	340	10.2	5.0	74,500	499	7,200	53	4,000	320			
		64,938			5,911			9.1	5,723			8.8	1,615			2.5		-4.2%		-30.8%		-35.0%			
Kyorin Pharmaceutical Co., Ltd.	End of Mar.	67,357	2,419	3.7	8,773	2,862	48.4	13.0	8,377	2,654	46.4	12.4	4,771	3,156	195.4	7.1	64,500	-2,857	5,800	-2,577	3,100	-1,671			
		59,657			4,633			7.8	5,022			8.4	2,340			3.9		3.6%		-8.7%		-2.1%			
Mochida Pharmaceutical Co., Ltd.	End of Mar.	61,611	1,954	3.3	7,984	3,351	72.3	13.0	8,874	3,852	76.7	14.4	5,106	2,766	118.2	8.3	63,800	2,189	8,100	-774	5,000	-106			
		57,236			5,524			9.7	5,836			10.2	4,655			8.1		5.8%		24.5%		7.9%			
Kissei Pharmaceutical Co., Ltd.	End of Mar.	56,642	-594	-1.0	1,790	-3,734	-67.6	3.2	2,650	-3,186	-54.6	4.7	1,946	-2,709	-58.2	3.4	59,900	3,258	3,300	650	2,100	154			
		54,718			1,506			2.8	1,562			2.9	1,318			2.4		1.2%		29.5%		7.7%			
Zenka Pharmaceutical Co., Ltd.	End of Mar.	54,344	-374	-0.7	1,349	-157	-10.4	2.5	1,699	137	8.8	3.1	1,300	-18	-1.4	2.4	55,000	656	2,200	501	1,400	100			
		54,024			4,320			8.0	4,419			8.2	5,610			10.4		2.8%		55.5%		64.8%			
Nippon Shinyaku Co., Ltd.	End of Mar.	53,798	-226	-0.4	2,441	-1,879	-43.5	4.5	2,830	-1,589	-36.0	5.3	1,517	-4,093	-73.0	2.8	55,300	1,502	4,400	1,570	2,500	983			
		41,493			1,331			3.2	1,051			2.5	634			1.5		1.7%		0.4%		-			
Fuso Pharmaceutical Industries, Ltd.	End of Mar.	42,283	790	1.9	916	-415	-31.2	2.2	777	-274	-26.1	1.8	-1,462	-2,096	-	-3.5	43,000	717	780	3	350	1,812			
		41,908			8,499			20.3	11,117			26.5	5,793			13.8		0.1%		-15.0%		-13.9%			
Torii Pharmaceutical Co., Ltd.	End of Mar.	40,477	-1,431	-3.4	7,606	-893	-10.5	18.8	7,646	-3,471	-31.2	18.9	4,179	-1,614	-27.9	10.3	40,500	23	6,500	-1,146	3,600	-579			
		41,432			2,555			6.2	2,901			7.0	583			1.4		26.5%		-		-			
Nikken Chemicals Co., Ltd.	End of Mar.	39,050	-2,382	-5.7	630	-1,925	-75.3	1.6	1,607	-1,294	-44.6	4.1	806	223	38.3	2.1	49,400	10,350	-400	-2,007	-1,800	-2,606			
		20,357			819			4.0	847			4.2	338			1.7		28.0%		148.6%		104.3%			
Aska Pharmaceutical Co., Ltd.	End of Mar.	23,672	3,315	16.3	444	-375	-45.8	1.9	708	-139	-16.4	3.0	416	78	23.1	1.8	30,300	6,628	1,760	1,052	850	434			
		20,125			6,550			32.5	6,864			34.1	3,590			17.8		-0.8%		-20.5%		15.2%			
Seikagaku Corporation	End of Mar.	20,971	846	4.2	6,997	447	6.8	33.4	7,796	932	13.6	37.2	3,473	-117	-3.3	16.6	20,800	-171	6,200	-1,596	4,000	527			
		22,794			2,581			11.3	1,199			5.3	404			1.8		14.6%		-90.2%		-53.6%			
Toyama Chemical Co., Ltd.	End of Mar.	21,032	-1,762	-7.7	1,516	-1,065	-41.3	7.2	1,021	-178	-14.8	4.9	646	242	59.9	3.1	24,100	3,068	100	-921	300	-346			
		17,538			845			4.8	634			3.6	464			2.6		5.7%		26.7%		-55.5%			
Nippon Chemiphar Co., Ltd.	End of Mar.	18,358	820	4.7	963	118	14.0	5.2	789	155	24.4	4.3	1,819	1,355	292.0	9.9	19,400	1,042	1,000	211	810	-1,009			
		9,997			722			7.2	847			8.5	485			4.9		0.1%		-10.4%		-7.0%			
Wakamoto Pharmaceutical Co., Ltd.	End of Mar.	10,142	145	1.5	650	-72	-10.0	6.4	731	-116	-13.7	7.2	441	-44	-9.1	4.3	10,150	8	655	-76	410	-31			